Dynamic biomarker signatures
EP4771392A1Pending Publication Date: 2026-07-08APRICITY HEALTH LLC
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- APRICITY HEALTH LLC
- Filing Date
- 2024-08-30
- Publication Date
- 2026-07-08
AI Technical Summary
Technical Problem
Current cancer treatments with immune checkpoint inhibitors often take months to determine patient responsiveness, leading to unnecessary hardships and delayed administration of combination therapies.
Method used
A method involving dynamic biomarker signatures, where a panel of biomarkers (such as CA6, CDNF, MIA, MYOC, NEFL, and TCL1B) is analyzed at multiple time points to predict non-response to immune checkpoint inhibitor monotherapy, and subsequently, a therapeutic targeting VSIG4 is administered.
Benefits of technology
This approach allows for early identification of non-responders to immune checkpoint inhibitors, enabling timely administration of alternative therapies like VSIG4 targeting, potentially improving treatment outcomes and reducing patient suffering.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024044575_06032025_PF_FP_ABST
Abstract
The present disclosure provides methods of identifying a subject with cancer that is non-responsive a treatment (e.g., immune checkpoint inhibitor monotherapy), wherein the cancer has an altered (e.g., increased or decreased) expression level of a panel of biomarkers, and methods of using the same to provide a combination therapy (e.g., a therapeutic targeting myeloid immune suppressive checkpoint (e.g., VSIG4) and an immune checkpoint inhibitor) to the subject with cancer.
Need to check novelty before this filing date? Find Prior Art